Zambian COVID-19 National Awareness Day 2024
Related Enduring Materials
Saturday, 16 March 2024
About this program
The WHO declared the end of the COVID-19 pandemic as a public health emergency of international concern. With hospitalization and death rates in decline and a high population immunity, the disease became an established and ongoing health issue.
However, the risk of emerging variants remained, as well as the continuing need for medical education. This referred to knowledge of reliable and accurate diagnostic tools, staying up-to-date with recommendations and guidelines, and pharmacological properties of SARS-CoV-2 antiviral drugs, among other aspects. In addition, the epidemiology of long COVID showed worrisome rates, and an increased understanding of its management and outcomes was much needed.
Certain comorbidities have been associated with poor COVID-19 outcomes, including diabetes, obesity, hypertension, chronic obstructive pulmonary disease etc. Understanding risk factors and pharmacological properties, including drug-drug interactions, of SARS-CoV-2 antiviral drugs was instrumental to timely and comprehensive care of patients with a high risk of developing a severe disease form.
To this end, The Zambian COVID-19 National Awareness Day was aimed at raising awareness and facilitating education among healthcare professionals, public health experts, policymakers, and community representatives on disease burden, risk factors, and clinical management related to COVID-19. The program was tailored to the national healthcare system, accessible therapeutic options, and epidemiological patterns.
Program Director
Local Chair
General Information
- Keynote Lectures
- Panel Discussion
- Audience Discussion
- Infectious disease clinicians, clinical virologists
- Pulmonologists, internal medicine doctors, cardiologists, neurologists,
- Immunologists, epidemiologists
- Pharmacists, pharmacologists, nurses
- Public health officials
- Community representatives
- Understand the COVID-19 epidemiology, pathology, and risk factors for poor outcomes
- Identify accessible diagnostic, prevention, and therapeutic options
- Comprehend pharmacological properties of antiviral drugs for COVID-19, and employ a drugdrug
interaction checker to assess potential harmful interactions
-Define main clinical considerations for COVID-19 management in diverse patient populations
(e.g. immunocompromised, renal impairment, pregnancy, or breastfeeding)
Practical Information
Translation will not be provided.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
